Novel Biomarkers for Alzheimer's Disease: Plasma Neurofilament Light and Cerebrospinal Fluid
Blood-based biomarkers, particularly NfL and plasma p-tau, represent a transformative advancement in the diagnosis and management of Alzheimer's disease. Their integration with consistent CSF biomarkers (T-tau, p-tau, Aβ42, and NfL) is strongly recommended for both clinical applications and research, offering a more accessible and reliable approach to addressing the challenges of Alzheimer's disease diagnosis and care.
Authors
- Daniel Naawenkangua Abukuri (ORCID: https://orcid.org/0000-0001-6794-635X)
Institutions
- University of Ghana (GH)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_096481
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00